Maximal androgen blockade for advanced prostate cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 331-340

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

androgen receptor; anti androgens; maximal androgen blockade; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADVANCED CANCER; ALCOHOL INTOLERANCE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HEMATURIA; HIGH RISK PATIENT; HORMONE RESPONSIVE ELEMENT; HUMAN; LIVER TOXICITY; NONHUMAN; PROSTATE CANCER; REVIEW; RISK REDUCTION; TRANSCRIPTION REGULATION; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TOSYL COMPOUNDS; WITHHOLDING TREATMENT;

EID: 42949165043     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.004     Document Type: Review

References (37)

1. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an anti-androgen. Clinical and Investigative Medicine 5 4 (1982) 267-275
2. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 1 (2004 Jan) 33-39
3. Partin A., and Coffey D. In: Walsh P. (Ed). Campbell's urology. 7th edn. (1998), WB Saunders, Philadelphia 1399
4. Kuil C.W., Berrevoets C.A., and Mulder E. Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. The Journal of Biological Chemistry 270 (1995) 27569-27576
5. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22 3 (2004 Sep) 179-184
6. Hodgson M.C., Astapova I., Hollenberg A.N., et al. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Research 67 17 (2007 Sep 1) 8388-8395
7. Hu X., and Lazar M.A. Transcriptional repression by nuclear hormone receptors. Trends in Endocrinology and Metabolism 11 (2000) 6-10
8. Bouchal J., Baumforth K.R., Sváchová M., et al. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. The Journal of Pharmacy and Pharmacology 57 1 (2005 Jan) 83-92
9. Gottlieb B., Vasiliou D.M., Lumbroso R., et al. Analysis of exon 1 mutations in the androgen receptor gene. Human Mutation 14 (1999) 527-539
10. Culig Z., Hoffmann J., Erdel M., et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer 81 (1999) 242-251
11. Kolvenbag G.J.C.M., Furr B.J.A., and Blackledge G.R.P. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer and Proststic Diseases 1 (1998) 307-314
12. Eisenberger M.A., Blumenstein B.A., Crawford E.D., et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. The New England Journal of Medicine 339 15 (1998) 1036-1042
13. McLeod D.G. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. The Oncologist 2 (1997) 18-27
14. Schellhammer P.F., Sharifi R., Block N.L., et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final results of a multicentre, double-blind, randomized trial. British Journal of Urology 80 (1997) 278
15. Titus M.A., Schell M.J., Lih F.B., et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 13 (2005 Jul 1) 4653-4657
16. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. The Journal of Urology 149 3 (1993 Mar) 607-609
17. Small E.J., and Srinivas S. The anti androgen withdrawal syndrome: experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76 (2005) 1428-3418
18. Fuse H., Korenaga S., Sakari M., et al. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. The Prostate 67 6 (2007 May 1) 630-637
19. Bohl C.E., Gao W., Miller D.D., et al. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 102 17 (2005 Apr 26) 6201-6206
20. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. The New England Journal of Medicine 321 (1989) 419-424
21. Klotz L. Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU International 87 (2001) 806-813
22. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
23. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361-376
24. Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment for advanced prostatic cancer. Available from:. http://www.ahcpr.gov/clinic/tp/prostp.htm [accessed 27 01 04]
25. Klotz L.H., and Newman T. Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence. The Canadian Journal of Urology 3 3 (1996 Sep) 246-250
26. Bennett C.L., Tosteson T.D., Schmitt B., et al. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Diseases 2 1 (1999 Jan) 4-8
27. Klotz L., Schellhammer P., and Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU International 93 9 (2004 Jun) 1177-1182
28. Rothmann M., Li N., Chen G., et al. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 22 (2003) 239-264
29. Fisher L.D., Gent M., and Buller H.R. Active control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin and placebo. American Heart Journal 141 (2001) 26-32
30. Usami M., Akaza H., Arai Y., et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Diseases 10 2 (2007) 194-201
31. Moinpour C.M., Savage M.J., Troxel A., et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. Journal of the National Cancer Institute 90 20 (1998 Oct 21) 1537-1544
32. Yamada Y., Takahashi S., Fujimura T., et al. The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporosis International 19 3 (2008 Mar) 321-327 [Epub 2007 Sep 29]
33. Penson D., Ramsay S., Veenstra D., et al. The cost effectiveness of combined androgen blockade with bicalutamide and LHRH agonist in men with metastatic prostate cancer. The Journal of Urology 174 2 (2005) 547-552
34. Aprikian A.G., Fleshner N., Langleben A., et al. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer. The Canadian Journal of Urology 10 (2003) 1986-1994
35. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. Journal of Clinical Oncology 25 13 (2007 May 1) 1765-1771
36. Kassouf W., Tanguay S., and Aprikian A.G. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. The Journal of Urology 169 (2003) 1742-1744
37. Akaza H, Usami M et al. Updated results of the Japanese Bicalutamide Trial. Presented at the European Multidisciplinary Uro-Oncology Conference, Barcelona, Nov 2007.